These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37235785)

  • 1. EGFR-Targeted Liposomes Combined with Ginsenoside Rh2 Inhibit Triple-Negative Breast Cancer Growth and Metastasis.
    Gu H; Shi R; Xu C; Lv W; Hu X; Xu C; Pan Y; He X; Wu A; Li J
    Bioconjug Chem; 2023 Jun; 34(6):1157-1165. PubMed ID: 37235785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy.
    Hong C; Wang A; Xia J; Liang J; Zhu Y; Wang D; Zhan H; Feng C; Jiang X; Pan J; Wang J
    Int J Nanomedicine; 2024; 19():2879-2888. PubMed ID: 38525007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
    Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
    Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Chen W; Qiu Y
    Cell Biochem Biophys; 2015 Jun; 72(2):325-31. PubMed ID: 25561284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2.
    Li S; Gao Y; Ma W; Guo W; Zhou G; Cheng T; Liu Y
    Tumour Biol; 2014 Jun; 35(6):5593-8. PubMed ID: 24557544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells.
    Hossein-Nejad-Ariani H; Althagafi E; Kaur K
    Sci Rep; 2019 Feb; 9(1):2723. PubMed ID: 30804365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
    Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-functionalized therapeutic nanoplatform for treatment orthotopic triple negative breast cancer and bone metastasis.
    Li D; Ma S; Xu D; Meng X; Lei N; Liu C; Zhao Y; Qi Y; Cheng Z; Wang F
    Nanomedicine; 2023 Jun; 50():102669. PubMed ID: 36933756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 20(
    Liang Y; Zhao J; Zou H; Zhang J; Zhang T
    Oxid Med Cell Longev; 2022; 2022():6119737. PubMed ID: 35111279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced anti-glioma activity of annonaceous acetogenins based on a novel liposomal co-delivery system with ginsenoside Rh2.
    Ao H; Song H; Li J; Wang X
    Drug Deliv; 2024 Dec; 31(1):2324716. PubMed ID: 38555735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One Stone Four Birds: A Novel Liposomal Delivery System Multi-functionalized with Ginsenoside Rh2 for Tumor Targeting Therapy.
    Hong C; Liang J; Xia J; Zhu Y; Guo Y; Wang A; Lu C; Ren H; Chen C; Li S; Wang D; Zhan H; Wang J
    Nanomicro Lett; 2020 Jun; 12(1):129. PubMed ID: 34138128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
    Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
    Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
    Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
    Yuan Z; Jiang H; Zhu X; Liu X; Li J
    Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis.
    Lev S
    Biochem Soc Trans; 2020 Apr; 48(2):657-665. PubMed ID: 32311020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
    Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW
    Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.